查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790450

美國抗真菌藥物市場規模、佔有率和趨勢分析報告：按藥物類別、適應症、劑型、分銷管道和細分市場預測，2025-2030 年

U.S. Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), By Indication, By Dosage Form, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國抗真菌藥物市場摘要

美國抗真菌藥物市場規模預計在 2024 年為 60.5 億美元，預計在 2030 年將達到 72 億美元，2025 年至 2030 年的複合年成長率為 3.0%。真菌感染疾病的日益普及正在推動市場擴張。

真菌感染疾病的種類繁多，從足癬、癬和陰道酵母菌感染疾病到嚴重的全身性疾病，如念珠菌血症、麴菌症和毛黴菌病。疾病預防控制中心將耳Auris和抗藥性麴菌種視為嚴重威脅，需要改進治療方法方法並加強感染控制。美國抗真菌藥物產業受到真菌感染疾病持續增加的推動，主要發生在癌症患者、移植患者和愛滋病毒感染者等免疫免疫力缺乏的人群中，以及ICU入院人數的增加和導管和人工呼吸器等醫療設備使用增加。這些族群特別容易受到灰指甲和麴菌症等性行為感染，需要全身性抗真菌治療。此外，甲癬和皮膚絲狀菌症病等淺層真菌病仍然普遍存在且經常復發，對口服和外用抗真菌藥物的需求保持穩定。監測數據表明，非白色念珠菌引起大約三分之二的血流感染疾病，其中 6% 的分離株對Fluconazole有抗藥性，2% 對Echinocandins有抗藥性。

根據美國疾病管制與預防中心 (CDC) 2024 年 5 月的數據，每年有超過 7.5 萬例住院病例和近 900 萬人次門診就診，均與真菌感染有關。 2024 年 4 月的數據顯示，每年約有 2.5 萬例念珠菌症病病例，約三分之一的患者在住院期間死亡。公共衛生工作正在穩步提高人們對真菌感染的認知。 CDC 的「真菌疾病宣傳週」定於 2025 年 9 月舉行，旨在促進早期診斷並加強抗藥性監測。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國抗真菌藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國抗真菌藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 美國抗真菌藥物市場：產品線分析

第4章美國抗真菌藥物市場：藥物類別估計與趨勢分析

  • 藥品類別細分儀表板
  • 美國抗真菌藥物市場：藥物類別變化分析
  • 美國抗真菌藥物市場規模及趨勢分析（依藥物類別，2018-2030年）
  • Azole
  • Echinocandins
  • Polyenes
  • Allylamines
  • 其他

第5章：美國抗真菌藥物市場：適應症估計與趨勢分析

  • 指示細分儀表板
  • 美國抗真菌藥物市場：適應症變化分析
  • 美國抗真菌藥物市場規模及趨勢分析（按適應症，2018-2030）
  • 皮膚絲狀菌症
  • 麴菌症
  • 念珠菌症
  • 其他

第6章：美國抗真菌藥物市場：劑型估計與趨勢分析

  • 劑型細分細分儀表板
  • 美國抗真菌藥物市場：劑型變化分析
  • 美國抗真菌藥物市場規模及趨勢分析（按劑型，2018-2030）
  • 口服藥物
  • 軟膏
  • 粉末
  • 其他

第7章：美國抗真菌藥物市場：通路評估與趨勢分析

  • 分銷通路細分儀表板
  • 美國抗真菌藥物分銷管道：管道波動分析
  • 美國抗真菌藥物市場規模及趨勢分析（按分銷管道，2018-2030）
  • 醫院藥房
  • 零售藥局
  • 其他

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • Novartis Pharmaceuticals Corporation
    • Pfizer Inc.
    • Bayer AG
    • Sanofi.
    • Merck &Co., Inc.
    • GSK plc.
    • Abbott.
    • GLENMARK PHARMACEUTICALS INC., USA
    • Enzon Pharmaceuticals, Inc.
    • Astellas Pharma US, Inc.
Product Code: GVR-4-68040-668-1

U.S. Antifungal Drugs Market Summary

The U.S. antifungal drugs market was estimated at USD 6.05 billion in 2024 and is projected to reach USD 7.20 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing incidence of fungal infections drives market expansion.

Fungal infections cover a broad range of conditions, from athlete's foot, ringworm, and vaginal yeast infections to severe systemic diseases such as candidemia, aspergillosis, and mucormycosis. The CDC identifies Candida auris and resistant Aspergillus species as serious threats, necessitating therapeutic advances and enhanced infection control. The U.S. antifungal drugs industry is mainly driven by a consistent increase in fungal infections among immunocompromised groups, such as cancer patients, transplant recipients, and individuals with HIV; a rise in ICU admissions; and the increased use of medical devices such as catheters and ventilators. This population is particularly vulnerable to invasive infections such as candidemia and aspergillosis, which require systemic antifungal treatments. Furthermore, superficial fungal infections such as onychomycosis and dermatophytosis remain widespread and frequently recur, maintaining steady demand for oral and topical antifungal medications. Surveillance data show that non-albicans Candida species cause approximately two-thirds of bloodstream infections, with 6% of isolates resistant to fluconazole and 2% of C. glabrata isolates resistant to echinocandins, highlighting the need for newer and more effective antifungal therapies.

Systemic fungal infections continue to pose a significant healthcare challenge in the U.S. Each year, more than 75,000 hospitalizations and nearly 9 million outpatient visits are attributed to fungal diseases, as per the CDC in May 2024. As per April 2024 data, ab out 25,000 cases of candidemia occur annually, with roughly one-third of patients dying during their hospital stay. Public health initiatives are steadily raising awareness of fungal diseases. The CDC's Fungal Disease Awareness Week, scheduled for September 2025, aims to promote early diagnosis and enhance resistance surveillance.

U.S. Antifungal Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antifungal drugs market on the basis of drug class, indication, dosage form, and distribution channel:

  • Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others
  • Indication Outlook (Revenue, USD Billion, 2018 - 2030)
  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others
  • Dosage Form Outlook (Revenue, USD Billion, 2018 - 2030)
  • Oral Drugs
  • Ointments
  • Powders
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacies
  • Retails Pharmacies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug class
    • 1.2.2. Indication
    • 1.2.3. Dosage form
    • 1.2.4. Distribution channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Indication outlook
    • 2.2.3. Dosage form
    • 2.2.4. Distribution channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antifungal Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Antifungal Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. U.S. Antifungal Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antifungal Drugs Market: Drug class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. U.S. Antifungal Drugs Market: Drug Class Movement Analysis
  • 4.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Azoles
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Echinocandins
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Polyenes
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Allylamines
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antifungal Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Segment Dashboard
  • 5.2. U.S. Antifungal Drugs Market: Indication Movement Analysis
  • 5.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
  • 5.4. Dermatophytosis
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Aspergillosis
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Candidiasis
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

  • 6.1. Dosage Form Segment Dashboard
  • 6.2. U.S. Antifungal Drugs Market: Dosage Form Movement Analysis
  • 6.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Dosage Form, 2018 to 2030 (USD Billion)
  • 6.4. Oral Drugs
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Ointments
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Powders
    • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. U.S. Antifungal Distribution Channel: Indication Movement Analysis
  • 7.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5. Retails Pharmacies
    • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Novartis Pharmaceuticals Corporation
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bayer AG
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Sanofi.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Merck & Co., Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. GSK plc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Abbott.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. GLENMARK PHARMACEUTICALS INC., USA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Enzon Pharmaceuticals, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Astellas Pharma US, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 U.S. antifungal drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 4 U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
  • Table 5 U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Financial performance
  • Table 7 Key companies undergoing expansions
  • Table 8 Key companies undergoing acquisitions
  • Table 9 Key companies undergoing collaborations
  • Table 10 Key companies launching new products/services
  • Table 11 Key companies undergoing partnerships
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antifungal drugs market: market outlook
  • Fig. 10 U.S. antifungal drugs market competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antifungal drugs market driver impact
  • Fig. 16 U.S. antifungal drugs market restraint impact
  • Fig. 17 U.S. antifungal drugs market strategic initiatives analysis
  • Fig. 18 U.S. antifungal drugs market: drug class movement analysis
  • Fig. 19 U.S. antifungal drugs market: drug class outlook and key takeaways
  • Fig. 20 Azoles market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Echinocandins market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Polyenes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Allylamines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. antifungal drugs market: by indication, movement analysis
  • Fig. 26 U.S. antifungal drugs market: indication outlook and key takeaways
  • Fig. 27 Dermatophytosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Aspergillosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Candidiasis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. antifungal drugs market: by dosage form, movement analysis
  • Fig. 32 U.S. antifungal drugs market: dosage form outlook and key takeaways
  • Fig. 33 Oral drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Powders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. antifungal drugs market: by distribution channel, movement analysis
  • Fig. 38 U.S. antifungal drugs market: distribution channel outlook and key takeaways
  • Fig. 39 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 OtherOthers market estimates and forecasts, 2018 - 2030 (USD Million)